A Phase 1/2 interventional study of NH002 (Perflutren Lipid Microspheres) Injectable Suspension and Echocardiogram in Cardiac Disease, sponsored by Trust Bio-sonics, Inc.. Completed at 2 sites in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Trust Bio-sonics, Inc. · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Heart Diseases with a site in Taiwan — 4 open to participants now, 7 under way, 3 of them phase 3. Heart Diseases · Taiwan.
Among the 25 studies in Heart Diseases with a site in Taiwan, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2019, is the only one in phase 1/2, and was the 13th registered.
2,135 studies on the registry are indexed under Heart Diseases; 252 are open to participants now.
Browse Heart Diseases studies →4 of the 25 studies in Heart Diseases with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, Argentina, Australia and 35 more countries
Ages 50+
Eidos Therapeutics, a BridgeBio company · Sites in Taiwan, United States, Argentina and 21 more countries
Ages 18–75
Weill Medical College of Cornell University · Sites in Taiwan, United States, Australia and 23 more countries
Ages 18+ · Women only
Tri-Service General Hospital · Sites in Taiwan
Ages 18–100
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.
This study: 20 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 8 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 556 across the 22 interventional studies, 234 across the 3 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 25 have an industry lead sponsor. The 10 most frequent:
Trust Bio-sonics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Trust Bio-sonics, Inc. has 3 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Diseases with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06815627Phase 3Trust Bio-sonics, Inc.Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography | 2027-02 |
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Heart Diseases with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV endocardial border. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg. Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension · Diagnostic Test: Echocardiogram
NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
12-lead ECGs
Standard 12-lead ECGs will be assessed from pre-injection to 60 minutes post-injection for changes in QT/ corrected QT(QTc) interval (in ms) and ECG morphology; each standard 12-lead ECG assessment will be scored as either normal or abnormal
Time frame: From pre-injection to 60 minutes post injection
Body Temperature
Monitor for any changes in body temperature (in Celsius degree)
Time frame: From pre-injection to 120 minutes post injection
Heart Rate
Monitor for any changes in heart rate (in beats/min)
Time frame: From pre-injection to 120 minutes post injection
Respiratory Rate
Monitor for any changes in respiratory rate (in breaths/min)
Time frame: From pre-injection to 120 minutes post injection
Blood Pressure
Monitor for any changes in blood pressure (in mmHg)
Time frame: From pre-injection to 120 minutes post injection
Thrombin Time (TT) and Activated Partial Thromboplastin Time (aPTT)
Monitor for any changes in TT and aPTT
Time frame: From pre-injection to 240 minutes post-injection
Cardiac Troponin I
Monitor for any changes in Cardiac troponin I
Time frame: pre-injection and 240 minutes post-injection
Oxygen Saturation by Pulse Oximetry (SpO2)
Monitor for any changes in SpO2
Time frame: From pre-injection to 120 minutes post-injection
Rate of Any Potential Adverse Allergic Reaction
Monitor for any potential adverse allergic reaction
Time frame: From pre-injection to 240 minutes post-injection
Cardiac Troponin T
Monitor for any changes in Cardiac troponin T
Time frame: pre-injection and 240 minutes post-injection
Left Ventricular Opacification (LVO)
The percentage of subjects with moderate or complete left ventricular opacification (LVO), defined by an LVO grade of 2 (moderate) or 3 (complete), as assessed by the blinded central reader(s). The percentage of subjects with complete LVO, defined by an LVO grade of 3 (complete), as assessed by the blinded central reader(s)
Time frame: Image data obtained pre-injection and within 10 minutes post-injection
Left Ventricular Endocardial Border Delineation (LVEBD)
The change from baseline on the left ventricular endocardial border delineation (LVEBD) score, defined using a standard 12-segment model, as assessed by the blinded central reader(s). The left ventricular (LV) endocardium of the 4- or 2- chamber apical views are divided into 6 segments, with 2 basal, mid- and apical segments in each view. For each segment, LVEBD is graded as follows: 0= inadequate border (border not visible); 1= sufficient (border barely visible); 2= good (border clearly visible). A total delineation score (0-24) is obtained by adding the scores from the 6 individual segments in each of the 2 views. The changes from baseline on LVEBD score of subjects with suboptimal LVEBD at baseline, as defined by 2 or more contiguous segments of 6 segments that cannot be visualized reliably in either the apical 4 and/or the 2-chamber view, as assessed by the blinded central reader(s)
Time frame: Image data obtained pre-injection and within 10 minutes post-injection
Duration of Clinically Useful Contrast
A duration of clinically useful contrast calculated by measuring the time between the disappearance of shadowing effect (useful effect starts) and the time when moderate or full LV enhancement and contrast enhancement are no longer adequate (useful effect ends), as assessed by the blinded central reader(s)
Time frame: Image data obtained pre-injection and within 10 minutes post-injection
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Started | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 |
Standard 12-lead ECGs will be assessed from pre-injection to 60 minutes post-injection for changes in QT/ corrected QT(QTc) interval (in ms) and ECG morphology; each standard 12-lead ECG assessment will be scored as either normal or abnormal
| millisecond | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline (QT) | 393.9 ± 19.37 | 392.0 ± 24.07 | 386.3 ± 25.99 |
| Change of Baseline (QT) at 10 minutes post-dose | 2.8 ± 13.65 | -6.0 ± 13.16 | 6.8 ± 17.65 |
| Change of Baseline (QT) at 30 minutes post-dose | 10.8 ± 13.28 | 6.0 ± 12.59 | 16.0 ± 13.4 |
| Change of Baseline (QT) at 60 minutes post-dose | 7.1 ± 17.17 | 3.4 ± 17.17 | 10.6 ± 9.59 |
| Baseline (QTc) | 415.1 ± 21.71 | 415.9 ± 20.38 | 404.6 ± 15.32 |
| Change of baseline (QTc) at 10 minutes post-dose | 1.3 ± 13.92 | -6.4 ± 10.95 | 7.8 ± 7.7 |
| Change of baseline (QTc) at 30 minutes post-dose | 0.4 ± 14.25 | -1.3 ± 12.14 | 8.8 ± 9.17 |
| Change of baseline (QTc) at 60 minutes post-dose | -0.1 ± 13.03 | -3.0 ± 11.96 | 6.9 ± 5.88 |
Monitor for any changes in body temperature (in Celsius degree)
| Celsius degree | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline | 36.76 ± 0.294 | 36.73 ± 0.306 | 36.76 ± 0.385 |
| Change from baseline at 5 minutes post-dose | -0.01 ± 0.215 | -0.02 ± 0.195 | -0.01 ± 0.268 |
| Change from baseline at 10 minutes post-dose | -0.01 ± 0.312 | 0.07 ± 0.235 | -0.06 ± 0.207 |
| Change from baseline at 30 minutes post-dose | -0.07 ± 0.328 | 0.11 ± 0.215 | 0 ± 0.2 |
| Change from baseline at 60 minutes post-dose | -0.08 ± 0.457 | 0.05 ± 0.271 | -0.18 ± 0.313 |
| Change from baseline at 120 minutes post-dose | -0.07 ± 0.442 | 0.1 ± 0.283 | -0.02 ± 0.518 |
Monitor for any changes in heart rate (in beats/min)
| beats/minute | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline | 70.1 ± 9.93 | 71.3 ± 7.73 | 69.0 ± 8.06 |
| Change from baseline at 10 minutes post-dose | -0.7 ± 2.71 | -0.1 ± 5.87 | -0.1 ± 3.73 |
| Change from baseline at 30 minutes post-dose | -3.0 ± 5.34 | -1.3 ± 5.99 | -0.3 ± 6.85 |
| Change from baseline at 60 minutes post-dose | -0.9 ± 5.96 | -1.2 ± 4.37 | 0.7 ± 4.56 |
| Change from baseline at 120 minutes post-dose | 4.9 ± 10.29 | 6.8 ± 12.4 | 8.3 ± 9.9 |
Monitor for any changes in respiratory rate (in breaths/min)
| breaths/minute | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline | 15.6 ± 3.55 | 15.1 ± 2.07 | 16.9 ± 4.44 |
| Change from baseline at 10 minutes post-dose | 0.6 ± 3.8 | -0.6 ± 3.29 | -1.4 ± 3.12 |
| Change from baseline at 30 minutes post-dose | 0.9 ± 3.09 | -0.8 ± 3.28 | -1.3 ± 4.71 |
| Change from baseline at 60 minutes post-dose | 0.5 ± 3.85 | -0.9 ± 2.75 | -2.3 ± 4.09 |
| Change from baseline at 120 minutes post-dose | 0.8 ± 3.43 | -0.5 ± 3.61 | -1.3 ± 4.48 |
Monitor for any changes in blood pressure (in mmHg)
| mmHg | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline (SBP) | 132.8 ± 14.93 | 106.8 ± 15.6 | 112.7 ± 16.33 |
| Change from baseline (SBP) at 10 minutes post-dose | -2.5 ± 9.48 | 0.5 ± 6.45 | -0.3 ± 7.76 |
| Change from baseline (SBP) at 30 minutes post-dose | -5.2 ± 11.54 | 4.8 ± 13.33 | 4.1 ± 9.46 |
| Change from baseline (SBP) at 60 minutes post-dose | -4.8 ± 15.03 | 1.5 ± 12.59 | 6.0 ± 10.44 |
| Change from baseline (SBP) at 120 minutes post-dose | -4.0 ± 13.1 | 7.6 ± 15.47 | 13.8 ± 19.6 |
| Baseline (DBP) | 85.2 ± 11.61 | 68.5 ± 13.3 | 71.5 ± 11.76 |
| Change from baseline (DBP) at 10 minutes post-dose | -2.6 ± 6.56 | 0 ± 4.92 | 2.6 ± 5.96 |
| Change from baseline (DBP) at 30 minutes post-dose | -3.9 ± 8.12 | 4.1 ± 10.66 | 3.1 ± 9.6 |
| Change from baseline (DBP) at 60 minutes post-dose | -3.0 ± 10.4 | 3.6 ± 11.52 | 7.8 ± 11.58 |
| Change from baseline (DBP) at 120 minutes post-dose | -2.3 ± 7.94 | 6.8 ± 14.16 | 8.7 ± 14.5 |
Monitor for any changes in TT and aPTT
| seconds | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline (TT) | 18.6 ± 3.145 | 17.81 ± 0.667 | 16.7 ± 1.836 |
| Change from baseline (TT) at 60 minutes post-dose | 0.22 ± 0.395 | -0.12 ± 0.387 | -0.24 ± 0.724 |
| Change from baseline (TT) at 120 minutes post-dose | 0.06 ± 0.528 | 0.05 ± 0.95 | -0.3 ± 0.662 |
| Change from baseline (TT) at 240 minutes post-dose | 0.11 ± 0.497 | -0.05 ± 0.62 | 0.31 ± 1.274 |
| Baseline (APTT) | 31.54 ± 3.888 | 28.76 ± 27.81 | 28.87 ± 2.796 |
| Change from baseline (APTT) at 60 minutes post-dose | -0.3 ± 2.625 | -1.05 ± 2.184 | -0.8 ± 2.921 |
| Change from baseline (APTT) at 120 minutes post-dose | -0.49 ± 3.11 | -0.48 ± 1.788 | -0.61 ± 2.586 |
| Change from baseline (APTT) at 240 minutes post-dose | -0.55 ± 3.191 | -0.68 ± 1.516 | -1.5 ± 2.375 |
Monitor for any changes in Cardiac troponin I
| ng/mL | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline (troponin I) | 0.005 ± 0.000 | 0.005 ± 0.000 | 0.005 ± 0.000 |
| 240 minutes after dosing (troponin I) | 0.005 ± 0.000 | 0.005 ± 0.000 | 0.005 ± 0.000 |
| Change from baseline (troponin I) at 240 minutes post-dose | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 |
Monitor for any changes in SpO2
| percentage | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline | 98.8 ± 1.06 | 98.9 ± 1.51 | 98.3 ± 1.14 |
| Change from baseline at 10 minutes post-dose | 0.4 ± 1.31 | 0.3 ± 0.62 | -0.4 ± 1.38 |
| Change from baseline at 30 minutes post-dose | 0.2 ± 1.27 | 0.3 ± 1.29 | -0.3 ± 0.87 |
| Change from baseline at 60 minutes post-dose | 0.5 ± 1.88 | 0.4 ± 1.38 | 0.8 ± 1.22 |
| Change from baseline at 120 minutes post-dose | 0 ± 1.13 | -0.2 ± 1.64 | 0.2 ± 0.94 |
Monitor for any potential adverse allergic reaction
| Participants | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Rate of Any Potential Adverse Allergic Reaction | 0 | 0 | 0 |
The percentage of subjects with moderate or complete left ventricular opacification (LVO), defined by an LVO grade of 2 (moderate) or 3 (complete), as assessed by the blinded central reader(s). The percentage of subjects with complete LVO, defined by an LVO grade of 3 (complete), as assessed by the blinded central reader(s)
| Participants | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| LVO grade of 2 (moderate) or 3 (complete) | 12 | 12 | 12 |
| LVO grade of 3 (complete) | 11 | 12 | 12 |
The change from baseline on the left ventricular endocardial border delineation (LVEBD) score, defined using a standard 12-segment model, as assessed by the blinded central reader(s). The left ventricular (LV) endocardium of the 4- or 2- chamber apical views are divided into 6 segments, with 2 basal, mid- and apical segments in each view. For each segment, LVEBD is graded as follows: 0= inadequate border (border not visible); 1= sufficient (border barely visible); 2= good (border clearly visible). A total delineation score (0-24) is obtained by adding the scores from the 6 individual segments in each of the 2 views. The changes from baseline on LVEBD score of subjects with suboptimal LVEBD at baseline, as defined by 2 or more contiguous segments of 6 segments that cannot be visualized reliably in either the apical 4 and/or the 2-chamber view, as assessed by the blinded central reader(s)
| score on a scale | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| LVEBD scores_Baseline (all subjects) | 11.5 ± 6.75 | 8.9 ± 4.89 | 9.7 ± 6.68 |
| LVEBD scores_Post-dose (all subjects) | 23.0 ± 3.46 | 23.8 ± 0.62 | 23.9 ± 0.29 |
| Change from baseline (all subjects) | 11.5 ± 7.22 | 14.8 ± 4.71 | 14.3 ± 6.59 |
| LVEBD scores_Baseline (subjects with suboptimal LVEBD at baseline) | 8.6 ± 4.48 | 7.4 ± 3.72 | 7.8 ± 6.65 |
| LVEBD scores_Post-dose (subjects with suboptimal LVEBD at baseline) | 22.7 ± 4.0 | 23.7 ± 0.67 | 23.9 ± 0.33 |
| Change from baseline (subjects with suboptimal LVEBD at baseline) | 14.1 ± 6.11 | 16.3 ± 3.56 | 16.1 ± 6.57 |
A duration of clinically useful contrast calculated by measuring the time between the disappearance of shadowing effect (useful effect starts) and the time when moderate or full LV enhancement and contrast enhancement are no longer adequate (useful effect ends), as assessed by the blinded central reader(s)
| minutes | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Duration of Clinically Useful Contrast | 7.2 ± 2.458 | 7.67 ± 1.684 | 3.59 ± 1.854 |
Monitor for any changes in Cardiac troponin T
| ng/L | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Baseline (troponin T) | 4.07 ± 2.53 | 1.5 ± 0.0 | 4.38 ± 1.824 |
| 240 minutes after dosing (troponin T) | 5.21 ± 1.368 | 2.3 ± 1.105 | 5.72 ± 4.387 |
| Change from baseline (troponin T) at 240 minutes post-dose | 1.14 ± 1.878 | 0.8 ± 1.105 | 1.34 ± 3.833 |
Collected over Each subject had to be carefully monitored for the development of any AEs throughout the study from the signing of the informed consent form to 7 days after receipt of the dose of study agent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Cohort 2 | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Cohort 3 | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| DizzinessNervous system disorders | 0/12 | 0/12 | 3/12 |
| Chest discomfortGeneral disorders | 0/12 | 0/12 | 2/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 | 2/12 |
| FlushingVascular disorders | 0/12 | 0/12 | 2/12 |
| PalpitationsCardiac disorders | 0/12 | 0/12 | 2/12 |
| Ocular hyperaemiaEye disorders | 0/12 | 0/12 | 2/12 |
| Chest painGeneral disorders | 0/12 | 1/12 | 1/12 |
| ChillsGeneral disorders | 0/12 | 0/12 | 1/12 |
| Head discomfortNervous system disorders | 0/12 | 0/12 | 1/12 |
| HeadacheNervous system disorders | 0/12 | 0/12 | 1/12 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 43.5 ± 14.77 | 38.8 ± 10.29 | 36.8 ± 11.42 | 39.7 ± 12.29 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Female | 4 | 7 | 6 | 17 |
| Male | 8 | 5 | 6 | 19 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 12 | 12 | 12 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Height(centimeter) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 168.4 ± 11.396 | 163.7 ± 10.93 | 166.74 ± 11.991 | 166.28 ± 11.29 |
| Weight(kilogram) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 76.88 ± 21.992 | 63.17 ± 13.131 | 73.59 ± 22.279 | 71.21 ± 19.933 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2019 to primary completion in Jul 2020, 7 months.
Results were first posted in Dec 2024, 4 years 5 months after primary completion. A results delay was requested in Jun 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perflutren
Trust Bio-sonics, Inc.